PD-L1 IHC 22C3 PHARMDX
Agilent Technologies, Inc. · Decision date Oct 2, 2015
What did the FDA approve?
The October 2, 2015 approval covers the PD-L1 IHC 22C3 pharmDx immunohistochemical assay from Agilent Technologies, Inc. The device detects PD-L1 protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue using monoclonal mouse anti-PD-L1 clone 22C3, the EnVision FLEX visualization system, and Autostainer Link 48. Expression is scored by tumor proportion score, the percentage of viable tumor cells showing partial or complete membrane staining.
A specimen is considered PD-L1 positive when TPS is at least 50% of viable tumor cells with membrane staining at any intensity. The stated purpose is to aid in identifying NSCLC patients for treatment with Keytruda (pembrolizumab). The source statement reports that intended use; it does not itself establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE PD-L1 IHC 22C3 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING: PD-L1 IHC 22C3 PHARMDX IS A QUALITATIVE IMMUNOHISTOCHEMICAL ASSAY USING MONOCLONAL MOUSE ANTI-PD-L1, CLONE 22C3 ANTIBODY INTENDED FOR USE IN THE DETECTION OF PD-L1PROTEIN IN FORMALIN FIXED, PARAFFIN EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48. PD-L1 PROTEIN EXPRESSION IS DETERMINED BY USING TUMOR PROPORTION SCORE (TPS), WHICH IS THE PERCENTAGE OF VIABLE TUMOR CELLS SHOWING PARTIAL OR COMPLETE MEMBRANE STAINING. THE SPECIMEN SHOULD BE CONSIDERED PD-L1 POSITIVE IF TPS >= 50% OF THE VIABLE TUMOR CELLS EXHIBIT MEMBRANE STAINING AT ANY INTENSITY. PD-L1 IHC 22C3 PHARMDX IS INDICATED AS AN AID IN IDENTIFYING NSCLC PATIENTS FOR TREATMENT WITH KEYTRUDA (PEMBROLIZUMAB).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Oct 2, 2015
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150013
- Regulatory pathway
- Premarket approval application
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- Decision code
- APPR
- Decision date
- Oct 2, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150013 received
Application receipt date recorded by FDA.
P150013 · FDA decision
APPR
P150013/S035 · Related supplement
PD-L1 IHC 22C3 pharmDx
P150013/S034 · Related supplement
PD-L1 IHC 22C3 pharmDx
Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 22C3 pharmDxP150013/S035 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S034 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
